GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parenteral Drugs (India) Ltd (BOM:524689) » Definitions » Return-on-Tangible-Equity

Parenteral Drugs (India) (BOM:524689) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Mar. 2022)


View and export this data going back to 2001. Start your Free Trial

What is Parenteral Drugs (India) Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Parenteral Drugs (India)'s annualized net income for the quarter that ended in Mar. 2022 was ₹952.52 Mil. Parenteral Drugs (India)'s average shareholder tangible equity for the quarter that ended in Mar. 2022 was ₹-8,240.31 Mil. Therefore, Parenteral Drugs (India)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 was Negative Tangible Equity%.

The historical rank and industry rank for Parenteral Drugs (India)'s Return-on-Tangible-Equity or its related term are showing as below:

BOM:524689's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.475
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Parenteral Drugs (India) Return-on-Tangible-Equity Historical Data

The historical data trend for Parenteral Drugs (India)'s Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parenteral Drugs (India) Return-on-Tangible-Equity Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - Negative Tangible Equity

Competitive Comparison of Parenteral Drugs (India)'s Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parenteral Drugs (India)'s Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s Return-on-Tangible-Equity falls into.



Parenteral Drugs (India) Return-on-Tangible-Equity Calculation

Parenteral Drugs (India)'s annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2022 )  (A: Mar. 2021 )(A: Mar. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2022 )  (A: Mar. 2021 )(A: Mar. 2022 )
=-763.619/( (-6828.77+-8240.306 )/ 2 )
=-763.619/-7534.538
=N/A %

Parenteral Drugs (India)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=952.516/( (0+-8240.306)/ 1 )
=952.516/-8240.306
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Parenteral Drugs (India)  (BOM:524689) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Parenteral Drugs (India) Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Parenteral Drugs (India)'s Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Parenteral Drugs (India) (BOM:524689) Business Description

Traded in Other Exchanges
N/A
Address
Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.

Parenteral Drugs (India) (BOM:524689) Headlines

No Headlines